GR1802
Phase 3Small molecule
GR1802 is one of 71 small molecule programs targeting Seasonal Allergic Rhinitis. It is currently in Phase 3.
3
Indications
8
Total Trials
5
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
50 competitors in Sinusitis
#DrugCompanyPhaseTrials
1Ketek
SanofiApproved
Avelox
BayerApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Kalydeco
Vertex PharmaceuticalsApproved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Nurtec
PfizerApproved
Cipro
BayerApproved
Omnicef
AbbVieApproved
Pulmicort
SSalix
Approved
Levaquin
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Seasonal Allergic Rhinitis3 trials
A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).
Active, not recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 2·NCT06315426·240 enrolled
Chronic Rhinosinusitis With Nasal Polyps2 trials
The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps
Active, not recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 2·NCT05873803·70 enrolled
Sinusitis1 trial
A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps
Active, not recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 3·NCT06516302·228 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GR1802. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details